Feedback PLC (LON:FDBK) shares soared in value on Thursday after saying its flagship imaging-based communication platform, Bleepa, has been awarded a place on the NHSx National Clinical Communication Tool (NCCT) framework.
The medical imaging specialist said the NCCT framework will provide a vehicle for NHS Trusts to buy Bleepa by drawing down from a £3mln centralised fund over two years, giving Bleepa national coverage and providing independent validation of the quality and suitability of the platform for frontline delivery, a stamp of approval that it said will allow it to drive sales in other markets.
WATCH: Feedback's Tom Oakley discusses plans for Bleepa rollout following £5.5mln raise
The framework will run for an initial period between August 3 2020 and August 3 2022 with a possible further extension for 12 months.
"Bleepa has set a new standard for medical communication tools. I am delighted Bleepa has been awarded a place on the NHSx Clinical Communication Tool framework which positions Bleepa in the vanguard of medical imaging communications and provides a vehicle for potential reimbursement whilst simultaneously making Bleepa available to the whole of the NHS", said Feedback chief executive Tom Oakley.
The company’s shares rocketed 82.2% to 2.05p in late-afternoon trading.
